-
Product Insights
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) - Drugs In Development, 2023’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Company Profile
Dominari Holdings Inc – Company Profile
Dominari Holdings Inc (Dominari Holdings), formerly AIkido Pharma Inc, a biotechnology company that develops early stage small-molecule anti-cancer therapeutics. Its therapy areas include acute myeloid leukemia, pancreatic cancer and acute lymphoblastic leukemia. The company pipeline products include KPC34 developed in preclinical studies for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia and DHA-dFdC developed in preclinical studies for treatment of pancreatic cancer. Dominari Holdings is headquartered in New York, the US.
Add to Basket